If the FDA grants this designation (which it has not yet), Lilly would receive more intensive FDA guidance and a potentially faster review
Neuroscience 120, 443453
Unpacking the Triple Action: GLP-1, GIP, and Glucagon Retatrutide stands out as a triple agonist, targeting GLP-1, GIP, and glucagon receptors
Disclaimer Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization
Selective modulation of A1 astrocytes by drug-loaded nano-structured gel in spinal cord injury
It is especially relevant for those reducing their dose, stopping medication, worried about appetite returning, or trying to maintain weight loss after treatment